Food and Fermentation Industries >

2024 , Vol. 50 >Issue 12: 284 - 291

DOI: https://doi.org/10.13995/j.cnki.11-1802/ts.036270

Intervention of astragaloside Ⅳ on chronic atrophic gastritis based on network pharmacology

  • BAO Zhewei ,
  • HU Shunan ,
  • YANG Lanzhu ,
  • YU Wenjuan ,
  • YANG Jingya
Expand
  • 1(College of Food Science and Technology, Shanghai Ocean University, Shanghai 201306, China)
    2(College of Life Science, Shanghai Ocean University, Shanghai 201306, China)
    3(Laboratory of Quality and Safety Risk Assessment for Aquatic Product on Storage and Preservation (Shanghai), Ministry of Agriculture, Shanghai 201306, China)
    4(National R&D Branch Center for Freshwater Aquatic Products Processing Technology (Shanghai), Shanghai 201306, China)

Received date: 2023-05-29

  Revised date: 2023-06-14

  Online published: 2024-07-11

Fold

Abstract

This study used network pharmacology to forecast and evaluate effectiveness in controlling chronic atrophic gastritis, laying the groundwork for its inclusion in functional foods.The target genes of astragaloside Ⅳ that control chronic atrophic gastritis were gathered for this experiment from databases such as Swiss Target Prediction, PharmaMapper, OMIM, etc.The target gene was identified by taking intersections.Based on the STRING database, a protein-protein interaction (PPI) network was created.Based on the centrality of the intermediate number, the PPI network did topology analysis using Cytoscape software, and simulated potential molecular docking outcome with Autodock Vina software.GO and KEGG enrichment analysis was conducted on the bioinformatics online platform to screen out relevant signal pathways.In vitro experiments were conducted by inducing GES-1 cells (human gastric mucosal epithelial cells) with MNNG (1-methyl-3-nitro-1-nitrosoguanidine) and treating them with astragaloside Ⅳ to detect cell viability and inflammatory factor secretion levels for validation.Finally, 53 potential targets were identified for the regulation of chronic atrophic gastritis by astragaloside Ⅳ, including 8 key genes.GO enrichment analysis showed that the vesicular cavity was the main site for biological processes to occur.The KEGG results indicated that proteoglycans in tumors were a key signaling pathway for astragaloside Ⅳ to regulate chronic atrophic gastritis.In vitro experiments found that astragaloside Ⅳ had a preventive and therapeutic effect on MNNG-induced cell damage, and could downregulate IL-6, IL-8, IL-1β, and TNF-α (P<0.05).This study showed that astragaloside Ⅳ could operate as a functional factor for the prevention and treatment of chronic atrophic gastritis and could exercise its anti-chronic atrophic gastritis impact through many targets and pathways.

Key words： astragaloside Ⅳ; chronic atrophic gastritis; homologous; network pharmacology; molecular docking

Cite this article

BAO Zhewei , HU Shunan , YANG Lanzhu , YU Wenjuan , YANG Jingya . Intervention of astragaloside Ⅳ on chronic atrophic gastritis based on network pharmacology[J]. Food and Fermentation Industries, 2024 , 50(12) : 284 -291 . DOI: 10.13995/j.cnki.11-1802/ts.036270

References

[1] 赵佳琛, 王艺涵, 金艳, 等.经典名方中黄芪的本草考证[J].中国实验方剂学杂志, 2022, 28(10):337-346.
ZHAO J C, WANG Y H, JIN Y, et al.Herbal textual research on astragali Radix in famous classical formulas[J].Chinese Journal of Experimental Traditional Medical Formulae, 2022, 28(10):337-346.
[2] 宋沁洁, 李国峰, 李咸慰, 等.黄芪药食同源现状分析[J].沈阳药科大学学报, 2023, 40(4):509-517.
SONG Q J,LI G F,LI X W, et al.Analysis of the current situation of astragalus medicine food homologous[J].Journal of Shenyang Pharmaceutical University, 2023, 40(4):509-517.
[3] TAN P, YEOH K G.Genetics and molecular pathogenesis of gastric adenocarcinoma[J].Gastroenterology, 2015, 149(5):1153-1162.e3.
[4] CAI T T, ZHANG C Z, ZHAO Z M, et al.The gastric mucosal protective effects of astragaloside IV in mnng-induced GPL rats[J].Biomedicine & Pharmacotherapy, 2018, 104(1):291-299.
[5] 黄红, 吕静薇, 陈颖, 等.我国中药健康产品管理及市场概况[J].中草药, 2021, 52(3):902-908.
HUANG H, LYU J W, CHEN Y, et al.Management and market general situation of Chinese medicine health products[J].Chinese Traditional and Herbal Drugs, 2021, 52(3):902-908.
[6] 王子怡, 王鑫, 张岱岩, 等.中医药网络药理学:《指南》引领下的新时代发展[J].中国中药杂志, 2022, 47(1):7-17.
WANG Z Y, WANG X, ZHANG D Y, et al.Traditional Chinese medicine network pharmacology:Development in new era under guidance of network pharmacology evaluation method guidance[J].China Journal of Chinese Materia Medica, 2022, 47(1):7-17.
[7] LIU X F, OUYANG S S, YU B, et al.PharmMapper server:A web server for potential drug target identification using pharmacophore mapping approach[J].Nucleic Acids Research, 2010, 38(Web server issue):W609-W614.
[8] WANG X, PAN C X, GONG J Y, et al.Enhancing the enrichment of pharmacophore-based target prediction for the polypharmacological profiles of drugs[J].Journal of Chemical Information and Modeling, 2016, 56(6):1175-1183.
[9] WANG X, SHEN Y H, WANG S W, et al.PharmMapper 2017 update:A web server for potential drug target identification with a comprehensive target pharmacophore database[J].Nucleic Acids Research, 2017, 45(W1):W356-W360.
[10] JOY M P, BROCK A, INGBER D E, et al.High-betweenness proteins in the yeast protein interaction network[J].Journal of Biomedicine and Biotechnology, 2005,2005(2):96-103.
[11] WANG K, LEI L, CAO J Y, et al.Network pharmacology-based prediction of the active compounds and mechanism of Buyang Huanwu Decoction for ischemic stroke[J].Experimental and Therapeutic Medicine, 2021, 22(4):1050.
[12] GOULET C R, CHAMPAGNE A, BERNARD G, et al.Cancer-associated fibroblasts induce epithelial-mesenchymal transition of bladder cancer cells through paracrine IL-6 signalling[J].BMC Cancer, 2019, 19(1):137.
[13] THANASUPAWAT T, GLOGOWSKA A, NIVEDITA-KRISHNAN S, et al.Emerging roles for the relaxin/RXFP1 system in cancer therapy[J].Molecular and Cellular Endocrinology, 2019, 487:85-93.
[14] JIANG J Y, SHEN S X, DONG N N, et al.Correlation between negative expression of pepsinogen C and a series of phenotypic markers of gastric cancer in different gastric diseases[J].Cancer Medicine, 2018, 7(8):4068-4076.
[15] DE FÁTIMA FERREIRA BORGES DA COSTA J, DE CASTRO SANT′ ANNA C, MUNIZ J A P C, et al.Deregulation of the SRC family tyrosine kinases in gastric carcinogenesis in non-human primates[J].Anticancer Research, 2018, 38(11):6317-6320.
[16] LI W Q, HU N, WANG Z M, et al.Genetic variants in epidermal growth factor receptor pathway genes and risk of esophageal squamous cell carcinoma and gastric cancer in a Chinese population[J].PLoS One, 2013, 8(7):e68999.
[17] DENG T Y, SHEN P, LI A M, et al.CCDC65 as a new potential tumor suppressor induced by metformin inhibits activation of AKT1 via ubiquitination of ENO1 in gastric cancer[J].Theranostics, 2021, 11(16):8112-8128.
[18] DONG Z, GUO S, WANG Y, et al.USP19 enhances MMP2/MMP9-mediated tumorigenesis in gastric cancer[J].OncoTargets and Therapy, 2020, 13:8495-8510.
[19] CUI C, CHAKRABORTY K, TANG X, et al.Neutrophil elastase selectively kills cancer cells and attenuates tumorigenesis[J].Cell, 2021, 184(12):3163-3177.e21.
[20] SANG L, LV Z, SUN L P, et al.Impact of SNP-SNP interactions of DNA repair gene ERCC5 and metabolic gene GSTP1 on gastric cancer/atrophic gastritis risk in a Chinese population[J].World Journal of Gastroenterology, 2018, 24(5):602-612.
[21] LI Y F, XIA R, ZHANG B, et al.Chronic atrophic gastritis:A review[J].Journal of Environmental Pathology, Toxicology and Oncology: Official Organ of the International Society for Environmental Toxicology and Cancer, 2018, 37(3):241-259.
[22] TONG Y L, WANG R L, LIU X, et al.Zuojin pill ameliorates chronic atrophic gastritis induced by MNNG through TGF-β/PI3K/Akt axis[J].Journal of Ethnopharmacology, 2021, 271:113893.
[23] CHEN X, WANG R L, BAO C M, et al.Palmatine ameliorates Helicobacter pylori-induced chronic atrophic gastritis by inhibiting MMP-10 through ADAM17/EGFR[J].European Journal of Pharmacology, 2020, 882:173267.
[24] MACHADO J C, FIGUEIREDO C, CANEDO P, et al.A proinflammatory genetic profile increases the risk for chronic atrophic gastritis and gastric carcinoma[J].Gastroenterology, 2003, 125(2):364-371.
[25] 臧凯宏, 刘丽丽, 吴建军, 等.黄芪甲苷治疗溃疡性结肠炎和肝脏损伤共病的分子机制网络药理学研究[J].中国药物警戒, 2022, 19(11):1196-1201.
ZANG K H, LIU L L, WU J J, et al.Molecular mechanism of astragaloside IV in the treatment of ulcerative colitis and liver injury comorbidity based on network pharmacology[J].Chinese Journal of Pharmacovigilance, 2022, 19(11):1196-1201.
[26] 于乃馨, 李国琼, 李标, 等.基于网络药理学和分子对接探讨黄芪甲苷治疗糖尿病视网膜病变的作用机制[J].中国实验方剂学杂志, 2022, 28(13):209-216.
YU N X, LI G Q, LI B, et al.Mechanism of astragaloside Ⅳ in treating diabetic retinopathy based on network pharmacology and molecular docking[J].Chinese Journal of Experimental Traditional Medical Formulae, 2022, 28(13):209-216.
[27] 罗娇, 熊书, 马强, 等.基于网络药理学和分子对接探讨黄芪甲苷、木香烃内酯的抗乳腺癌机制[J].临床医学研究与实践, 2022, 7(35):1-4.
LUO J, XIONG S, MA Q, et al.Discussion on anti-breast cancer mechanism of astragaloside Ⅳ and costunolide based on network pharmacology and molecular docking[J].Clinical Research and Practice, 2022, 7(35):1-4.
[28] YANG L J, LIU X Y, ZHU J J, et al.Progress in traditional Chinese medicine against chronic gastritis:From chronic non-atrophic gastritis to gastric precancerous lesions[J].Heliyon, 2023, 9(6):e16764.
[29] 赵彩萍, 刘翠玲, 梁爽, 等.黄芪甲苷对脂多糖诱导人胃黏膜上皮细胞GES-1的抗炎作用及机制研究[J].中药新药与临床药理, 2020, 31(8):918-923.
ZHAO C P, LIU C L, LIANG S, et al.Anti- inflammatory effect and mechanism of astragaloside Ⅳ on human gastric mucosa epithelial cells (GES1) induced by LPS[J].Traditional Chinese Drug Research and Clinical Pharmacology, 2020, 31(8):918-923.
Options
Outlines

/

〈 〉

Powered by Beijing Magtech Co. Ltd,.